These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 12725233)

  • 21. New approaches in cancer pharmacology: drug design and development. Report of a European School of Oncology Task Force.
    Eur J Cancer; 1992; 28A(6-7):1190-200. PubMed ID: 1627393
    [No Abstract]   [Full Text] [Related]  

  • 22. [Value and applications of pharmacogenetics in oncology and hematology].
    Albin N; Massade L; Gouyette A
    Bull Cancer; 1997 Jun; 84(6):643-51. PubMed ID: 9295869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors.
    Sheng J; Srivastava S; Sanghavi K; Lu Z; Schmidt BJ; Bello A; Gupta M
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S26-S42. PubMed ID: 28921644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. American Society of Clinical Oncology-39th Annual Meeting. Investigational Drugs. 31 May-3 June 2003, Chicago, IL, USA.
    Erlich R; Durrance A
    IDrugs; 2003 Jul; 6(7):628-30. PubMed ID: 12906005
    [No Abstract]   [Full Text] [Related]  

  • 25. Research in Gene Diagnostics of Cancer Disease. Proceedings of a meeting. Munster, Germany, October 24-28, 1994.
    Gene; 1995 Jun; 159(1):1-135. PubMed ID: 7607563
    [No Abstract]   [Full Text] [Related]  

  • 26. American Society of Clinical Oncology-39th Annual Meeting. Taxanes. 31 May-3 June 2003, Chicago, IL, USA.
    Erlich R; Durrance A
    IDrugs; 2003 Jul; 6(7):621-2. PubMed ID: 12906002
    [No Abstract]   [Full Text] [Related]  

  • 27. [Thalidomide--new prospective therapy in oncology].
    Pałgan K; Pałgan I
    Wiad Lek; 2003; 56(9-10):455-9. PubMed ID: 15049211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO).
    Sandherr M; Hentrich M; von Lilienfeld-Toal M; Massenkeil G; Neumann S; Penack O; Biehl L; Cornely OA
    Ann Hematol; 2015 Sep; 94(9):1441-50. PubMed ID: 26193852
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abstracts of the Annual Meeting of the German and Austrian Society of Hematology and Oncology. Munich, Germany, 27-30 October 2002.
    Onkologie; 2002 Oct; 25 Suppl 4():1-303. PubMed ID: 12462220
    [No Abstract]   [Full Text] [Related]  

  • 30. German and Austrian Society of Hematology and Oncology annual meeting. Mannheim, Germany, September 30 - October 3, 2001. Abstracts.
    Onkologie; 2001 Sep; 24 Suppl 6():1-250. PubMed ID: 11727702
    [No Abstract]   [Full Text] [Related]  

  • 31. American Association of Cancer Research--95th annual meeting. Highlights. 27-31 March, 2004, Orlando, FL, USA.
    Kibble A; Davies J
    IDrugs; 2004 May; 7(5):416-9. PubMed ID: 15154096
    [No Abstract]   [Full Text] [Related]  

  • 32. [Requirements in clinical evaluation of drugs in oncology. Guidelines of the phase I/II study group of the Professional Society of Internal Oncology of the German Cancer Society].
    Queisser W; Hermann R; Edler L; Boerner D; Hinke A; Kaplan A; Pechan R; Peukert M; Rieder H; Sterz R
    Onkologie; 1990 Aug; 13(4):322-4. PubMed ID: 2234786
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacology and pharmacogenetics of chemotherapeutic agents.
    Dawood S; Leyland-Jones B
    Cancer Invest; 2009 Jun; 27(5):482-8. PubMed ID: 19479485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A celebration of the life and contributions of Merrill J. Egorin.
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):1-3. PubMed ID: 21107574
    [No Abstract]   [Full Text] [Related]  

  • 35. Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities.
    Venkatakrishnan K; Friberg LE; Ouellet D; Mettetal JT; Stein A; Trocóniz IF; Bruno R; Mehrotra N; Gobburu J; Mould DR
    Clin Pharmacol Ther; 2015 Jan; 97(1):37-54. PubMed ID: 25670382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Parasitic diseases in pediatric cancer patients].
    Bialek R
    Klin Padiatr; 2005 Nov; 217 Suppl 1():S85-90. PubMed ID: 16288354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [On possibilities of a directed therapy with cytostatics].
    Völker R; Eichler K
    Med Welt; 1967 Apr; 14():875-8. PubMed ID: 5585083
    [No Abstract]   [Full Text] [Related]  

  • 38. Meeting report: pharmacology in pediatric oncology. Summary of the 10th international expert meeting of the Kind Philipp Foundation for leukemia research, June 10 - 13, 2001 at the Schloss Reisensburg, Günzburg an der donau.
    Widemann BC; Boos J
    Klin Padiatr; 2002; 214(4):236-9. PubMed ID: 12165908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Continuing medical education in systemic treatment : Are the contents adequately conveyed?].
    Gschwend JE
    Urologe A; 2010 Aug; 49(8):925-9. PubMed ID: 20652677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. On clinical biochemical pharmacology of 5-fluorouracil and anticancer pyrimidines, Marseille, July 22-23, 1978, USA-France agreement in clinical trial and treatment research (NCI-INSERM).
    Bull Cancer; 1979; 66(1):37-100. PubMed ID: 33733
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.